Alyssum Therapeutics, which recently came out of stealth mode raising a total of $26M in Series A financing, added an additional $2M from FemHealth Ventures. Alyssum Therapeutics is developing AT-1965, a clinical stage, first in class small molecule CMTR2 inhibitor that converts immunologically cold tumors into hot and recruits a B cell-driven immune response against the tumor. High CMTR2 expression in tumors is associated with poor prognosis for many tumor types including breast cancers, positioning it as a novel target in cancer therapy. The recruitment of B cells has recently been reported to be the best indicator of long-term survival in cancer patients. Earlier this year, Alyssum had announced the dosing of the first patient with AT-1965.
